Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets OTCPK - Delayed Quote USD

Kiromic BioPharma, Inc. (KRBPQ)

Compare
0.1200
0.0000
(0.00%)
At close: April 7 at 9:38:51 AM EDT
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Cost of Revenue
8,067
8,067
2,677
--
--
Gross Profit
-8,067
-8,067
-2,677
--
--
Operating Expense
15,707
15,707
17,262
31,114.3000
25,305.7000
Operating Income
-23,774
-23,774
-19,939
-31,114.3000
-25,305.7000
Net Non Operating Interest Income Expense
-3,723
-3,723
-1,852
-166.5000
-12.2000
Other Income Expense
599
599
842
-3,450.2000
-270.8000
Pretax Income
-26,898
-26,898
-20,949
-34,731
-25,588.7000
Net Income Common Stockholders
-33,732
-33,732
-23,500
-35,075.8000
-25,810.7000
Diluted NI Available to Com Stockholders
-33,732
-33,732
-23,500
-35,075.8000
-25,810.7000
Basic EPS
-3.17
-3.17
-12.59
-64.42
-67.80
Diluted EPS
-3.17
-3.17
-12.59
-64.42
-67.80
Basic Average Shares
1,460.8830
1,460.8830
1,097.6300
544.4750
380.5690
Diluted Average Shares
1,460.8830
1,460.8830
1,097.6300
544.4750
380.5690
Total Operating Income as Reported
-23,774
-23,774
-19,939
-31,114.3000
-25,735.7000
Total Expenses
23,774
23,774
19,939
31,114.3000
25,305.7000
Net Income from Continuing & Discontinued Operation
-26,898
-26,898
-20,949
-34,731
-25,588.7000
Normalized Income
-26,898
-26,898
-19,219
-31,268
-25,264.5000
Interest Expense
3,723
3,723
1,852
166.5000
12.2000
Net Interest Income
-3,723
-3,723
-1,852
-166.5000
-12.2000
EBIT
-23,175
-23,175
-19,097
-34,564.5000
-25,576.5000
EBITDA
-20,941
-20,941
-16,876
-32,891.1000
-25,106.7000
Reconciled Cost of Revenue
8,067
8,067
2,677
--
--
Reconciled Depreciation
2,234
2,234
2,221
1,673.4000
469.8000
Net Income from Continuing Operation Net Minority Interest
-26,898
-26,898
-20,949
-34,731
-25,588.7000
Total Unusual Items Excluding Goodwill
--
--
-1,730
-3,463
-324.2000
Total Unusual Items
--
--
-1,730
-3,463
-324.2000
Normalized EBITDA
-20,941
-20,941
-15,146
-29,428.1000
-24,782.5000
12/31/2021 - 10/16/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers